PROSTATE LUNG COLORECTAL OVARIAN (PLCO) ETIOLOGIC AND EARLY MARKER STUDIES (EEMS)

前列腺癌、肺癌、结肠直肠癌、卵巢癌 (PLCO) 病因学和早期标志物研究 (EEMS)

• 批准号: 10862524
• 负责人: THOMAS RILEY
• 金额: $ 115.31万
• 依托单位: INFORMATION MANAGEMENT SERVICES, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-20 至 2024-07-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10862524
• 关键词: Area; Biocompatible Materials; Biological; Cancer Etiology; Colorectal; Colorectal Cancer; Contracts; Data; Etiology; Internet; Logistics; Lung; Malignant neoplasm of lung; Malignant neoplasm of ovary; Monitor; Ovarian; Participant; Peer Review; Process; Prostate; Qualifying; Research Personnel; Research Project Grants; Resources; Risk Factors; Sampling; Services; Specimen; System; Tissue Sample; Tissues; Update; biobank; data access system; early detection biomarkers; improved; programs; screening

The Etiologic and Early Marker Studies (EEMS) is a component of the Prostate Lung Colorectal and Ovarian (PLCO) Trial. By collecting biologic materials and risk factor information from participants, PLCO EEMS provides a rich resource for research on cancer etiology and early detection biomarkers. The PLCO Biorepository stores approximately 2.9 million biologic specimens collected from PLCO participants. These specimens and their associated data are available to all qualified researchers through an application and peer-review process. EEMS also covers tissue specimens from the LSS component of the National Lung Screening Trial (NLST).

病因学和早期标志物研究(EEM)是前列腺癌、肺脏、结直肠和卵巢(PLCO)试验的一个组成部分。通过收集参与者的生物材料和风险因素信息，PLCO 为癌症病因学和早期检测生物标志物的研究提供了丰富的资源。PLCO生物资料库存储了从PLCO参与者那里收集的大约290万个生物标本。所有合格的研究人员都可以通过申请和同行评审程序获得这些标本及其相关数据。EEMS还包括来自国家肺部筛查试验(NLST)的LSS部分的组织标本。